amiodarone has been researched along with Fatigue in 4 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sudden cardiac death was observed in 16 patients, 8 patients in each group." | 2.72 | Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. ( Crijns, HJ; Hagens, VE; Rienstra, M; Van Gelder, IC; Van Veldhuisen, DJ, 2006) |
| "Recent infection was present in 40." | 1.39 | Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance. ( Ajrouche, R; Al-Hajje, A; Awada, S; El-Helou, N; Rachidi, S; Salameh, P; Zein, S, 2013) |
| "Amiodarone is an effective treatment for atrial and ventricular arrhythmias, but its use is limited by a toxic adverse-effect profile." | 1.39 | Ventricular ectopy and QTc-interval prolongation associated with dronedarone therapy. ( Gonzalez, JE; Krantz, MJ; Sauer, WH, 2013) |
| "Arrhythmogenic right ventricular dysplasia is an inherited, progressive condition." | 1.31 | Arrhythmogenic right ventricular dysplasia. An illustrated review highlighting developments in the diagnosis and management of this potentially fatal condition. ( Fisher, NG; Gilbert, TJ, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Helou, N | 1 |
| Al-Hajje, A | 1 |
| Ajrouche, R | 1 |
| Awada, S | 1 |
| Rachidi, S | 1 |
| Zein, S | 1 |
| Salameh, P | 1 |
| Gonzalez, JE | 1 |
| Sauer, WH | 1 |
| Krantz, MJ | 1 |
| Hagens, VE | 1 |
| Rienstra, M | 1 |
| Van Veldhuisen, DJ | 1 |
| Crijns, HJ | 1 |
| Van Gelder, IC | 1 |
| Fisher, NG | 1 |
| Gilbert, TJ | 1 |
1 trial available for amiodarone and Fatigue
| Article | Year |
|---|---|
Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2006 |
3 other studies available for amiodarone and Fatigue
| Article | Year |
|---|---|
Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Anti-Inflammatory Agen | 2013 |
Ventricular ectopy and QTc-interval prolongation associated with dronedarone therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography, Amb | 2013 |
Arrhythmogenic right ventricular dysplasia. An illustrated review highlighting developments in the diagnosis and management of this potentially fatal condition.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventric | 2000 |